Impact of baseline lipoprotein and C-reactive protein levels on coronary atheroma regression following high-intensity statin therapy

American Journal of Cardiology

Volumn 114, Issue 10, 2014, Pages 1465-1472

  Puri, Rishi ^a   Nissen, Steven E ^a   Shao, Mingyuan ^a   Uno, Kiyoko ^a   Kataoka, Yu ^b   Kapadia, Samir R ^a   Tuzcu, E Murat ^a   Nicholls, Stephen J ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; C REACTIVE PROTEIN; CREATINE KINASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CREATINE KINASE BLOOD LEVEL; DISEASE SEVERITY; DRUG TOLERABILITY; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; ANGIOCARDIOGRAPHY; BLOOD; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE COURSE; DOSE RESPONSE; ENDOSCOPIC ECHOGRAPHY; FOLLOW UP; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PLAQUE, ATHEROSCLEROTIC; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

BIOMARKERS; C-REACTIVE PROTEIN; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS; MALE; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC; PROSPECTIVE STUDIES; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84908318230     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2014.08.009     Document Type: Article

References (30)

1. C. Baigent, L. Blackwell, J. Emberson, L.E. Holland, C. Reith, N. Bhala, R. Peto, E.H. Barnes, A. Keech, J. Simes, and R. Collins Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
2. Z. Reiner, A.L. Catapano, G. De Backer, I. Graham, M.R. Taskinen, O. Wiklund, S. Agewall, E. Alegria, M.J. Chapman, P. Durrington, S. Erdine, J. Halcox, R. Hobbs, J. Kjekshus, P.P. Filardi, G. Riccardi, R.F. Storey, and D. Wood ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Eur Heart J 32 2011 1769 1818
3. N.J. Stone, J.G. Robinson, A.H. Lichtenstein, C.N. Bairey Merz, C.B. Blum, R.H. Eckel, A.C. Goldberg, D. Gordon, D. Levy, D.M. Lloyd-Jones, P. McBride, J.S. Schwartz, S.T. Shero, S.C. Smith Jr., K. Watson, and P.W. Wilson 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 63 2014 2889 2934
4. J.C. Tardif, F. Lesage, F. Harel, P. Romeo, and J. Pressacco Imaging biomarkers in atherosclerosis trials Circ Cardiovasc Imaging 4 2011 319 333
5. S.J. Nicholls, A. Hsu, K. Wolski, B. Hu, O. Bayturan, A. Lavoie, K. Uno, E.M. Tuzcu, and S.E. Nissen Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome J Am Coll Cardiol 55 2010 2399 2407
6. R. Puri, K. Wolski, K. Uno, Y. Kataoka, K.L. King, T.D. Crowe, S.R. Kapadia, E.M. Tuzcu, S.E. Nissen, and S.J. Nicholls Left main coronary atherosclerosis progression, constrictive remodeling, and clinical events JACC Cardiovasc Interv 6 2013 29 35
7. S.E. Nissen, E.M. Tuzcu, P. Schoenhagen, B.G. Brown, P. Ganz, R.A. Vogel, T. Crowe, G. Howard, C.J. Cooper, B. Brodie, C.L. Grines, and A.N. DeMaria Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial JAMA 291 2004 1071 1080
8. S.E. Nissen, S.J. Nicholls, I. Sipahi, P. Libby, J.S. Raichlen, C.M. Ballantyne, J. Davignon, R. Erbel, J.C. Fruchart, J.C. Tardif, P. Schoenhagen, T. Crowe, V. Cain, K. Wolski, M. Goormastic, and E.M. Tuzcu Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial JAMA 295 2006 1556 1565
9. S.J. Nicholls, C.M. Ballantyne, P.J. Barter, M.J. Chapman, R.M. Erbel, P. Libby, J.S. Raichlen, K. Uno, M. Borgman, K. Wolski, and S.E. Nissen Effect of two intensive statin regimens on progression of coronary disease N Engl J Med 365 2011 2078 2087
10. S.J. Nicholls, G.L. Bakris, J.J. Kastelein, V. Menon, B. Williams, J. Armbrecht, P. Brunel, M. Nicolaides, A. Hsu, B. Hu, H. Fang, R. Puri, K. Uno, Y. Kataoka, D. Bash, and S.E. Nissen Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial JAMA 310 2013 1135 1144
11. S.E. Nissen, E.M. Tuzcu, H.B. Brewer, I. Sipahi, S.J. Nicholls, P. Ganz, P. Schoenhagen, D.D. Waters, C.J. Pepine, T.D. Crowe, M.H. Davidson, J.E. Deanfield, L.M. Wisniewski, J.J. Hanyok, L.M. Kassalow Investigators AIATE Effect of ACAT inhibition on the progression of coronary atherosclerosis N Engl J Med 354 2006 1253 1263
12. S.E. Nissen, J.C. Tardif, S.J. Nicholls, J.H. Revkin, C.L. Shear, W.T. Duggan, W. Ruzyllo, W.B. Bachinsky, G.P. Lasala, and E.M. Tuzcu Effect of torcetrapib on the progression of coronary atherosclerosis N Engl J Med 356 2007 1304 1316
13. S.E. Nissen, S.J. Nicholls, K. Wolski, J. Rodes-Cabau, C.P. Cannon, J.E. Deanfield, J.P. Despres, J.J. Kastelein, S.R. Steinhubl, S. Kapadia, M. Yasin, W. Ruzyllo, C. Gaudin, B. Job, B. Hu, D.L. Bhatt, A.M. Lincoff, and E.M. Tuzcu Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial JAMA 299 2008 1547 1560
14. S.E. Nissen, S.J. Nicholls, K. Wolski, R. Nesto, S. Kupfer, A. Perez, H. Jure, R. De Larochelliere, C.S. Staniloae, K. Mavromatis, J. Saw, B. Hu, A.M. Lincoff, and E.M. Tuzcu Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial JAMA 299 2008 1561 1573
15. P.J. Barter, M. Caulfield, M. Eriksson, S.M. Grundy, J.J. Kastelein, M. Komajda, J. Lopez-Sendon, L. Mosca, J.C. Tardif, D.D. Waters, C.L. Shear, J.H. Revkin, K.A. Buhr, M.R. Fisher, A.R. Tall, and B. Brewer Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2007 2109 2122
16. S.E. Nissen, T. Tsunoda, E.M. Tuzcu, P. Schoenhagen, C.J. Cooper, M. Yasin, G.M. Eaton, M.A. Lauer, W.S. Sheldon, C.L. Grines, S. Halpern, T. Crowe, J.C. Blankenship, and R. Kerensky Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial JAMA 290 2003 2292 2300
17. S.E. Nissen, E.M. Tuzcu, P. Libby, P.D. Thompson, M. Ghali, D. Garza, L. Berman, H. Shi, E. Buebendorf, and E.J. Topol Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial JAMA 292 2004 2217 2225
18. P. Schoenhagen, S.K. Sapp, E.M. Tuzcu, W.A. Magyar, J. Popovich, M. Boumitri, D.G. Vince, T. Crowe, and S.E. Nissen Variability of area measurements obtained with different intravascular ultrasound catheter systems: impact on clinical trials and a method for accurate calibration J Am Soc Echocardiogr 16 2003 277 284
19. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
20. M.J. Blaha, M.G. Silverman, and M.J. Budoff Is there a role for coronary artery calcium scoring for management of asymptomatic patients at risk for coronary artery disease?: Clinical risk scores are not sufficient to define primary prevention treatment strategies among asymptomatic patients Circ Cardiovasc Imaging 7 2014 398 408
21. M.T. Cooney, A. Dudina, P. Whincup, S. Capewell, A. Menotti, P. Jousilahti, I. Njolstad, R. Oganov, T. Thomsen, A. Tverdal, H. Wedel, L. Wilhelmsen, I. Graham Investigators S Re-evaluating the Rose approach: comparative benefits of the population and high-risk preventive strategies Eur J Cardiovasc Prev Rehabil 16 2009 541 549
22. R. Puri, S.E. Nissen, M. Shao, C.M. Ballantyne, P.J. Barter, M.J. Chapman, R. Erbel, P. Libby, J.S. Raichlen, K. Uno, Y. Kataoka, and S.J. Nicholls Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy Eur Heart J 34 2013 3182 3190
23. P.M. Ridker, N. Rifai, L. Rose, J.E. Buring, and N.R. Cook Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events N Engl J Med 347 2002 1557 1565
24. S. Mora, R.J. Glynn, and P.M. Ridker High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy Circulation 128 2013 1189 1197
25. J.D. Otvos, D. Collins, D.S. Freedman, I. Shalaurova, E.J. Schaefer, J.R. McNamara, H.E. Bloomfield, and S.J. Robins Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial Circulation 113 2006 1556 1563
26. S. Mora, J.E. Buring, and P.M. Ridker Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events Circulation 129 2014 553 561
27. J.G. Robinson, S. Wang, B.J. Smith, and T.A. Jacobson Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk J Am Coll Cardiol 53 2009 316 322
28. S.M. Boekholdt, B.J. Arsenault, S. Mora, T.R. Pedersen, J.C. LaRosa, P.J. Nestel, R.J. Simes, P. Durrington, G.A. Hitman, K.M. Welch, D.A. DeMicco, A.H. Zwinderman, M.B. Clearfield, J.R. Downs, A.M. Tonkin, H.M. Colhoun, A.M. Gotto Jr., P.M. Ridker, and J.J. Kastelein Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis JAMA 307 2012 1302 1309
29. P.M. Ridker, E. Danielson, F.A. Fonseca, J. Genest, A.M. Gotto Jr., J.J. Kastelein, W. Koenig, P. Libby, A.J. Lorenzatti, J.G. MacFadyen, B.G. Nordestgaard, J. Shepherd, J.T. Willerson, and R.J. Glynn Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
30. R. Puri, P. Libby, S.E. Nissen, K. Wolski, C.M. Ballantyne, P.J. Barter, M.J. Chapman, R. Erbel, J.S. Raichlen, K. Uno, Y. Kataoka, E.M. Tuzcu, and S.J. Nicholls Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN Eur Heart J Cardiovasc Imaging 15 2014 380 388